A marked molecular heterogeneity of growth hormone (GH) detected in the plasma but not pituitary of a patient with acromegaly: comparison with other acromegalics and an implication for discrepant plasma levels of GH and insulin-like growth factor
- PMID: 1506622
- DOI: 10.1007/BF03348758
A marked molecular heterogeneity of growth hormone (GH) detected in the plasma but not pituitary of a patient with acromegaly: comparison with other acromegalics and an implication for discrepant plasma levels of GH and insulin-like growth factor
Abstract
We experienced a 41-year-old acromegalic male (Case 1) in whom the basal plasma GH was extremely high (320-450 ng/mL) but plasma IGF-I was only slightly elevated (2.0-2.8 U/mL). His nutritional condition and associated diabetes mellitus did not appear to be responsible for the relatively low IGF-I level, and a GH-autoantibody in the plasma was absent. We thus performed gel filtration analyses of his plasma and somatotroph adenoma to determine elution patterns of immunoreactive (IR) and receptor active (RA) GH. For comparison, the same studies were carried out on plasmas and somatotroph adenomas obtained from three other acromegalics (Cases 2-4) whose basal plasma GH and IGF-I levels were 22-45 ng/mL and 3.5-6.0 U/mL, respectively. IR GH in Case 1's plasma distributed over an extremely wide range keeping similar titers rather than showing three discernible components (big-big, big, and little GH) as did plasmas and adenomas from Cases 2-4. And, most of the IR GH in Case 1's plasma was eluted in such fractions that contained low levels of RA GH, indicating a minor proportion of biologically active GH. However, interestingly, the chromatographic profile and total GH content of Case 1's adenoma were similar to those of Cases 2-4's adenomas. These results may, at least in part, explain the discrepancy between the plasma GH and IGF-I levels of Case 1. The unexpectedly different GH elution patterns between the plasma and adenoma from this patient, may suggest a contribution of certain plasma factor(s) to the unusual chromatographic profile of plasma GH.
Similar articles
-
Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.Clin Endocrinol (Oxf). 2003 Sep;59(3):328-38. doi: 10.1046/j.1365-2265.2003.01851.x. Clin Endocrinol (Oxf). 2003. PMID: 12919156
-
In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide.Eur J Endocrinol. 1995 Dec;133(6):686-90. doi: 10.1530/eje.0.1330686. Eur J Endocrinol. 1995. PMID: 8548053 Clinical Trial.
-
Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.PLoS One. 2013 Sep 9;8(9):e73543. doi: 10.1371/journal.pone.0073543. eCollection 2013. PLoS One. 2013. PMID: 24039977 Free PMC article.
-
Hormonal diagnosis of GH hypersecretory states.J Endocrinol Invest. 2003;26(10 Suppl):27-35. J Endocrinol Invest. 2003. PMID: 15497657 Review.
-
How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review.Pituitary. 2018 Jun;21(3):310-322. doi: 10.1007/s11102-018-0884-4. Pituitary. 2018. PMID: 29605877 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources